This version was machine-translated from German and has not been medically reviewed. The authoritative version is the German version.

Fever and neutropenia – risk score (SPOG 2010)

Four weighted variables (chemotherapy, Hb, leukocytes, platelets), collected at reassessment after 8–24 hours – from 9 points increased risk of serious complications; with Rackoff classification

Previous chemotherapy more intensive than ALL maintenance therapy
Hemoglobin ≥ 90 g/l (≥ 9 g/dl)
Leukocytes < 0.3 G/l
Platelets < 50 G/l
Rackoff 1996 (optional)

Calculation aid for healthcare professionals: the calculator reproduces what the sources cited assign to the inputs. Clinical assessment and every treatment decision remain with the treating physician. Inputs and results are not stored.

Frequently asked questions

Fever and neutropenia – risk score (SPOG 2010): What does this calculator compute?

SPOG-2010 score (Ammann 2010) for predicting severe complications in children with fever and chemotherapy-induced neutropenia at reassessment after 8–24 hours (chemotherapy more intensive than ALL maintenance 4, Hb ≥ 9 g/dl 5, leukocytes < 0.3 G/l 3, platelets < 50 G/l 3 points; ≥ 9 increased risk) – supplemented by the Rackoff classification 1996 (monocytes and temperature).

Fever and neutropenia – risk score (SPOG 2010): Which sources is this calculator based on?

Rackoff WR, Gonin R, Robinson C, Kreissman SG, Breitfeld PB: Predicting the risk of bacteremia in children with fever and neutropenia (J Clin Oncol 14:919–924) (1996); Klaassen RJ, Goodman TR, Pham B, Doyle JJ: 'Low-risk' prediction rule for pediatric oncology patients presenting with fever and neutropenia (J Clin Oncol 18:1012–1019) (2000); Ammann RA, Bodmer N, Hirt A, et al.: Predicting adverse events in children with fever and chemotherapy-induced neutropenia: the prospective multicenter SPOG 2003 FN study (J Clin Oncol 28:2008–2014) (2010); Santolaya ME, Alvarez AM, Becker A, et al.: Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, and fever (J Clin Oncol 19:3415–3421) (2001)